HIGHFDA DRUG

Zydus Icosapent Ethyl Capsules Recalled for Oxidized Ingredient in 60,541 Bottles (2026)

Zydus Pharmaceuticals USA Inc. is recalling 60,541 bottles of Icosapent Ethyl Capsules, 1 g, 120 capsules per bottle, distributed nationwide in the United States. The recall cites oxidized Icosapent Ethyl causing red dots inside capsules and melted capsules. Patients should stop using the medicine immediately and contact Zydus Pharmaceuticals USA Inc. or their clinician for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
March 9, 2026
Status
ACTIVE
Severity
6/10

Quick Facts at a Glance

Recall Date
March 9, 2026
Hazard Level
HIGH
Brands
ICOSAPENT ETHYL, Zydus Pharmaceuticals USA
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
ICOSAPENT ETHYL, Zydus Pharmaceuticals USA
Product type
Icosapent Ethyl Capsules
Model numbers
Lot #: S2520249, S2520250, S2520267, Exp. Date 2027/Jan, S2520303, S2520305, S2520332, Exp. Date 2027/Feb +3 more
UPC codes
70710-1592, 70710-1738, 70710-1738-4, 70710-1592-7
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    March 9, 2026

  2. Reported by FDA DRUG

    March 18, 2026

  3. RecallRadar source check

    April 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Zydus Pharmaceuticals (USA) Inc or your healthcare provider for guidance. Notification method: Letter

About This Product

Icosapent Ethyl is a prescription omega-3 fatty acid therapy used to treat high triglyceride levels. The 1 g capsule comes in a 120-count bottle and is distributed nationwide in the United States.

Why This Is Dangerous

Oxidation of the active ingredient can produce physical changes in the capsule, including red dots and melting, which may affect safety and efficacy.

Industry Context

This recall is not described as part of a broader industry pattern.

Real-World Impact

Patients using this prescription therapy may need to discontinue use and seek clinician guidance. The recall could disrupt ongoing treatment for high triglycerides.

Practical Guidance

How to identify if yours is affected

  1. Verify the product is Icosapent Ethyl Capsules, 1 g, 120-count, Rx only.
  2. Check NDC 70710-1592-7 on the bottle.

Where to find product info

FDA recall page for D-0400-2026 and the recall notice from Zydus Pharmaceuticals USA Inc.

What timeline to expect

Refund or replacement timelines are not specified. Follow recall instructions in the notification letter.

If the manufacturer is unresponsive

  • Document all communications with Zydus Pharmaceuticals USA Inc.
  • If the company is slow, contact your healthcare provider for guidance and consider filing a complaint with the FDA.
  • Keep copies of all notices and correspondence.

How to prevent similar issues

  • Verify NDC and lot numbers when receiving prescriptions.
  • Report any adverse events to your clinician and the FDA if observed.
  • Keep recall notifications for future reference.

Documentation advice

Retain recall letters, bottle labels, NDC, lot numbers, Expiration dates, and any correspondence with the company or clinician.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Product: Icosapent Ethyl Capsules, 1 g, 120 capsules per bottle, Rx only Manufacturer: Softgel Healthcare Pvt. Ltd., India Distributor: Zydus Pharmaceuticals USA Inc., Pennington, NJ 08534 NDC: 70710-1592-7 Recall date: 2026-03-09 Quantity: 60,541 bottles Distribution: Nationwide in the United States Lot numbers/exp dates: Lot #: S2520249; S2520250; S2520267; Exp. Date 2027/Jan; S2520303; S2520305; S2520332; Exp. Date 2027/Feb; S2540208; S2540209; Exp. Date 2027/Apr

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • Exp. Dates 2027/Jan, 2027/Feb, 2027/Apr

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
6/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Details

Model Numbers
Lot #: S2520249
S2520250
S2520267
Exp. Date 2027/Jan
S2520303
+6 more
UPC Codes
70710-1592
70710-1738
70710-1738-4
+1 more
Affected States
ALL
Report Date
March 18, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

Taro Pharmaceuticals Withdraws Diclofenac Sodium Gel Over Viscosity Issues

Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.

BEEKEEPER'S NATURALS USA
Microbial Contamination
Read more
Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

SUN PHARMACEUTICAL INDUSTRIES
Labeling: Not
Read more